Stock AXGN AXOGEN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News AxoGen, Inc.

Equities

AXGN

US05463X1063

Real-time Estimate Cboe BZX
Other stock markets
 01:57:11 2024-05-01 pm EDT 		5-day change 1st Jan Change
6.52 USD +1.72% Intraday chart for AxoGen, Inc. -4.66% -4.10%
Apr. 29 Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix CI
Mar. 08 Axogen Insider Sold Shares Worth $319,891, According to a Recent SEC Filing MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™
GL
Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix
CI
Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
GL
Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
AQ
Axogen Insider Sold Shares Worth $319,891, According to a Recent SEC Filing
MT
AxoGen, Inc. Announces Executive Changes
CI
AxoGen Files $100 Million Mixed-Securities Shelf
MT
Health Care Down After Mixed Earnings -- Health Care Roundup
DJ
Transcript : AxoGen, Inc., Q4 2023 Earnings Call, Mar 05, 2024
AxoGen: Q4 Earnings Snapshot
AQ
AxoGen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
GL
Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
AQ
AxoGen, Inc. Provides Earnings Guidance for the Fiscal Year 2024
CI
North American Morning Briefing : S&P 500 Futures -2-
DJ
Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
GL
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
GL
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
AQ
AxoGen Says Trial of Axoguard Nerve Cap Met Primary Endpoint of Pain Reduction
MT
Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AXGN Stock
  4. News AxoGen, Inc.